Algernon Pharmaceuticals Inc said that it had included nicotinate and pamoate as novel salt forms of DMT as part of its intellectual property patent applications filed in early 2021.
Nicotinate and pamoate are commonly used counterions when producing salts, Algernon noted.
Since a novel salt form of a drug is a new and separate structure from the original compound and is considered a new composition of matter, it anchored Algernon’s novel patent filings.
READ: Algernon Pharmaceuticals begins manufacturing Repirinast and launches new chronic kidney disease research program
Algernon also announced that in its binding study of nicotinate and pamoate, the salts showed that they had similar binding to the 5-HT2A and sigma-1 receptors, which are key receptors in the brain that are activated by DMT.
The results may assist with the efficacy of DMT as a potential treatment for stroke, Algernon said.
In a statement, Algernon told investors that it believes that it has maximized its intellectual property position around DMT, having filed patent applications for novel bioactive salt forms as well as dosing, formulation, and method of use patent applications for stroke rehabilitation.
“Shortly after filing our PCT application, we received a Written Opinion from the International Searching Authority that DMT nicotinate and DMT pamoate are novel and non-obvious, and appear to be patentable,” said Christopher J Moreau, CEO of Algernon.
“Since DMT on its own is naturally occurring and is therefore unpatentable as a new chemical entity, Algernon’s strategy is to ensure that along with trying to achieve good clinical data, the company has a correspondingly strong intellectual property position that is unique and protectable.”
Vancouver-based Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets.
Contact Angela at angela@proactiveinvestors.com
Follow her on Twitter @AHarmantas